Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
APGE Apogee Therapeutics Inc.
- Stocks
- Healthcare
- NASDAQ: APGE
Price (delayed)
$42.98
Market cap
$2.56B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.6
Enterprise value
$2.46B
We are a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD) and related inflammatory and immunology (I&I) indications with
Highlights
The company's EPS rose by 31% YoY but it fell by 9% QoQ
APGE's net income has dropped by 98% year-on-year and by 13% since the previous quarter
The quick ratio has plunged by 59% YoY and by 15% from the previous quarter
Key stats
What are the main financial stats of APGE
Market
Valuations
Earnings
Shares outstanding
59.53M
Market cap
$2.56B
Enterprise value
$2.46B
Price to earnings (P/E)
N/A
Price to book (P/B)
3.8
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$241.79M
Net income
-$205.39M
EBIT
-$205.29M
EBITDA
-$202.64M
Free cash flow
-$193.13M
Per share
Balance sheet
Liquidity
EPS
-$3.6
EPS diluted
-$3.6
Free cash flow per share
-$3.32
Book value per share
$11.32
Revenue per share
$0
TBVPS
$12.27
Total assets
$714.16M
Total liabilities
$40.8M
Debt
$11.82M
Equity
$673.36M
Working capital
$488.57M
Debt to equity
0.02
Current ratio
15.82
Quick ratio
15.57
Net debt/EBITDA
0.47
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-27%
Return on equity
-28.3%
Return on invested capital
-35.8%
Return on capital employed
-30.1%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
APGE stock price
How has the Apogee Therapeutics stock price performed over time
Intraday
-1.31%
1 week
4.37%
1 month
8.87%
1 year
14.71%
YTD
-5.12%
QTD
15.04%
Financial performance
How have Apogee Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$241.79M
Net income
-$205.39M
Gross margin
N/A
Net margin
N/A
Apogee Therapeutics's operating income has shrunk by 104% YoY and by 11% QoQ
APGE's net income has dropped by 98% year-on-year and by 13% since the previous quarter
Price vs fundamentals
How does APGE's price correlate with its fundamentals
Growth
What is Apogee Therapeutics's growth rate over time
Valuation
What is Apogee Therapeutics stock price valuation
P/E
N/A
P/B
3.8
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS rose by 31% YoY but it fell by 9% QoQ
APGE's equity is down by 16% year-on-year and by 6% since the previous quarter
APGE's P/B is 4.1% above its last 4 quarters average of 3.7
Efficiency
How efficient is Apogee Therapeutics business performance
The company's return on invested capital rose by 32% YoY
Apogee Therapeutics's ROA has decreased by 17% from the previous quarter and by 16% YoY
APGE's return on equity is down by 17% since the previous quarter and by 4.4% year-on-year
Dividends
What is APGE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for APGE.
Financial health
How did Apogee Therapeutics financials performed over time
Apogee Therapeutics's total liabilities has surged by 84% YoY and by 10% QoQ
The quick ratio has plunged by 59% YoY and by 15% from the previous quarter
The debt is 98% less than the equity
APGE's equity is down by 16% year-on-year and by 6% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.